Akero therapeutics inc AKRO.US 總覽分析

美股醫療保健
(AKRO 無簡報檔)

AKRO 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面評分較低,若以價值投資為目標,已經有長期投資部位可能需陸續減碼

AKRO 近期報酬表現

4.22%

Akero therapeutics inc

4.57%

同產業平均

3.26%

S&P500

與 AKRO 同產業的標的表現

  • ETNB 89bio inc
    價值 1 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分
    查看更多

AKRO 公司資訊

Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

AKRO 股價